Gómez-Aguayo et al., 2018
ViewHTML| Publication | Publication Date | Title |
|---|---|---|
| US12059449B2 (en) | Ophthalmic composition for treatment of dry eye disease | |
| Erb et al. | German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye | |
| Sall et al. | Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease | |
| Pflugfelder et al. | Challenges in the clinical measurement of ocular surface disease in glaucoma patients | |
| Katz et al. | Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost | |
| Manni et al. | The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension | |
| Realini et al. | West Indies Glaucoma Laser Study (WIGLS): 1. 12-month efficacy of selective laser trabeculoplasty in Afro-Caribbeans with glaucoma | |
| Tomić et al. | Influence of BAK‐Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open‐Angle Glaucoma | |
| Peace et al. | Polyquaternium-1–preserved travoprost 0.003% or benzalkonium chloride–preserved travoprost 0.004% for glaucoma and ocular hypertension | |
| Lee et al. | Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study | |
| Kim et al. | Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial | |
| Kumar et al. | Ocular surface disease with BAK preserved travoprost and polyquaternium 1 (Polyquad) preserved travoprost | |
| Gómez-Aguayo et al. | A phase III randomized clinical trial of a 0.5% timolol+ 0.2% brimonidine+ 2.0% dorzolamide fixed combination, preservative-free ophthalmic solution vs. 0.5% timolol+ 0.2% brimonidine+ 2.0% dorzolamide fixed combination in patients with controlled primary open-angle glaucoma | |
| Wong et al. | Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride | |
| JP2025004186A (en) | Methods for Treating Ocular Surface Pain | |
| Muz et al. | Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension | |
| Roberti et al. | Prospective, randomized, single masked, parallel study exploring the effects of a preservative-free ophthalmic solution containing hyaluronic acid 0.4% and taurine 0.5% on the ocular surface of glaucoma patients under multiple long-term topical hypotensive therapy | |
| Tanihara et al. | Crossover randomized study of pharmacologic effects of Ripasudil–Brimonidine fixed-dose combination versus ripasudil or brimonidine | |
| Sezgin Akçay et al. | The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension | |
| Kaarniranta et al. | Pharmacokinetics, efficacy, and safety of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in healthy volunteers: a phase I comparison vs. the corresponding preservative-free monotherapies | |
| Singh et al. | Long-term safety and efficacy evaluation of travoprost intracameral implant based on pooled analyses from two phase III trials | |
| Wy et al. | Comparison of two combinations of maximum medical therapy for lowering intraocular pressure in primary open-angle glaucoma | |
| Ogami et al. | The effect of diquafosol ophthalmic solution on clinical parameters and visual function in soft contact lens-related dry eye | |
| Fakhraie et al. | Effects of postoperative cyclosporine ophthalmic emulsion 0.05%(Restasis) following glaucoma surgery | |
| Kim et al. | Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration |